October 19, 2022

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

Powerful platform reveals the lung environment for diagnosing lung diseases

Research Scientist Lydia Bederka, PhD, will present results of the Company’s research into the use of flow cytometry for analyzing the lung environment to detect diseases of the lung at the American College of Chest Physicians (CHEST) 2022 conference Oct. 16-19, 2022. The presentation, Sputum Analysis By Flow Cytometry To Assess Lung Health, will be part of the Lung Cancer Assessment and Risk Calculations session on Oct. 19 beginning at 11:15 a.m. (ET). Dr. Bederka will present data showing how flow cytometry can identify reproducible cell populations from whole sputum samples that can be used in the development of diagnostics for COPD and asthma, and has been used to develop bioAffinity’s initial product, CyPath^® Lung, that detects early-stage lung cancer.